Skip to main content
. Author manuscript; available in PMC: 2022 May 1.
Published in final edited form as: Mol Cancer Ther. 2021 Sep 4;20(11):2189–2197. doi: 10.1158/1535-7163.MCT-21-0126

Figure 3. Repotrectinib treatment of ALK aberrant cell line and xenograft model shows target engagement of downstream effector pathways.

Figure 3.

In vitro: protein levels were assessed by western blot analysis after treatment of cells with the indicated concentrations of repotrectinib: (A) Total ALK and p-ALK in NB-1; (B) Trk and p-Trk in SK-N-DZ and NB-1; (C) using the indicated antibodies to assess multiple downstream signaling pathways in SK-N-DZ and NB-1. (D) In vivo: MSKNBL-40352 (ALK 1275Q, ALK amplified, MYCN amplified) tumor lysates from the three treatment arms (vehicle, ensartinib, and repotrectinib (TPX-0005) were analyzed by western blot using the indicated antibodies.